PharVision Advisers’s Nano X Imaging NNOX Stock Holding History

PharVision Advisers’s Portfolio NNOX Stock Details NNOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,194	Closed	-$56.2K	–	904
2025 Q3	$56.2K	Buy	+15,194	New	+$67.6K	0.03%	648
2025 Q1	–	Sell	-11,139	Closed	-$80.2K	–	442
2024 Q4	$80.2K	Buy	+11,139	New	+$71.3K	0.07%	377

Other funds holding NNOX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PharVision Advisers's NNOX Position: Q4 2025 in Review

PharVision Advisers sold out of Nano X Imaging (NNOX) in Q4 2025, closing a stake of 15,194 shares — an estimated $56.2K sold.

PharVision Advisers first reported a position in NNOX in Q4 2024 and held it in 2 quarters. The position peaked at $80.2K in Q4 2024. 113 funds tracked by Wall St. Rank hold NNOX as of Q4 2025.

PharVision Advisers reported no remaining Nano X Imaging position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 15,194 Nano X Imaging shares in Q4 2025, an estimated $56.2K.
PharVision Advisers first reported a position in Nano X Imaging in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Nano X Imaging position peaked at $80.2K in Q4 2024.
113 funds tracked by Wall St. Rank held Nano X Imaging as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.